Raymond James Financial’s Phathom Pharmaceuticals PHAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$326K Sell
44,597
-3,427
-7% -$32.3K ﹤0.01% 4814
2026
Q2
$521K Buy
48,024
+21,696
+82% +$248K ﹤0.01% 4483
2026
Q1
$293K Buy
26,328
+1,938
+8% +$24.5K ﹤0.01% 4671
2025
Q4
$405K Buy
24,390
+10,996
+82% +$157K ﹤0.01% 4405
2025
Q3
$158K Buy
13,394
+10,220
+322% +$105K ﹤0.01% 4674
2025
Q2
$30.4K Buy
+3,174
New +$17.6K ﹤0.01% 5404
2025
Q1
– Sell
-455,837
Closed -$3.7M – 4916
2024
Q4
$3.7M Buy
+455,837
New +$5.65M ﹤0.01% 2521

Other funds holding PHAT

Raymond James Financial's PHAT Position: Q3 2026 in Review

Raymond James Financial reduced its Phathom Pharmaceuticals (PHAT) stake by 7.1% in Q3 2026, selling an estimated $32.3K and leaving 44,597 shares worth $326K. The position accounts for ﹤0.01% of the portfolio, ranked #4814.

Raymond James Financial first reported a position in PHAT in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.7M in Q4 2024. 161 funds tracked by Wall St. Rank hold PHAT as of Q3 2026.

  • Raymond James Financial held 44,597 shares of Phathom Pharmaceuticals worth $326K as of Q3 2026.
  • Raymond James Financial sold 3,427 Phathom Pharmaceuticals shares in Q3 2026, an estimated $32.3K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #4814 holding.
  • Raymond James Financial first reported a position in Phathom Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's Phathom Pharmaceuticals position peaked at $3.7M in Q4 2024.
  • 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.